{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:11:22Z","timestamp":1760955082437},"reference-count":18,"publisher":"Royal College of Psychiatrists","issue":"1","license":[{"start":{"date-parts":[[2018,1,2]],"date-time":"2018-01-02T00:00:00Z","timestamp":1514851200000},"content-version":"unspecified","delay-in-days":9498,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Psychiatry"],"published-print":{"date-parts":[[1992,1]]},"abstract":"<jats:p>This paper concerns certain questions which arose during the analysis of a trial showing positive effects of tacrine in Alzheimer's disease. Cognitive improvement occurred during the first two weeks, reached a maximum at one month and was maintained during the rest of the three-month treatment period. Rebound effects were not detected in any of the key outcome variables, but were suggested by one of the supporting cognitive tests and other measures. Practice effects occurred on tests which were repeated at short intervals or too frequently. The paper discusses the significance of these findings for the interpretation of other trials and for practical management.<\/jats:p>","DOI":"10.1192\/bjp.160.1.36","type":"journal-article","created":{"date-parts":[[2008,10,15]],"date-time":"2008-10-15T04:56:07Z","timestamp":1224046567000},"page":"36-40","source":"Crossref","is-referenced-by-count":35,"title":["Tacrine in Alzheimer's Disease"],"prefix":"10.1192","volume":"160","author":[{"given":"Sarah","family":"Eagger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Morant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Sahakian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"170","published-online":{"date-parts":[[2018,1,2]]},"reference":[{"key":"S0007125000034929_ref11","doi-asserted-by":"publisher","DOI":"10.1093\/geront\/9.3_Part_1.179"},{"key":"S0007125000034929_ref1","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.114.512.797"},{"key":"S0007125000034929_ref7","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100029899"},{"key":"S0007125000034929_ref13","first-page":"29","article-title":"Effect of tetrahydroaminoacridine on cognition, function and behaviour in Alzheimer's disease","volume":"144","author":"Molloy","year":"1991","journal-title":"Canadian Medical Association Journal"},{"key":"S0007125000034929_ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/1.4.233"},{"key":"S0007125000034929_ref15","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3932(90)90055-S"},{"key":"S0007125000034929_ref14","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1176\/ajp.141.11.1356","article-title":"A new rating scale for Alzheimer's disease","volume":"141","author":"Rosen","year":"1984","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000034929_ref17","first-page":"145","article-title":"Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients","volume":"16","author":"Summers","year":"1981","journal-title":"Biological Psychiatry"},{"key":"S0007125000034929_ref16","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.8.1225"},{"key":"S0007125000034929_ref9","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1979.tb05903.x"},{"key":"S0007125000034929_ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198611133152001"},{"key":"S0007125000034929_ref2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6723.495"},{"key":"S0007125000034929_ref6","volume-title":"Food and Drug Administration, Division of Neuropharmagological Drug Products (1990) Draft guideline for the clinical evaluation of antidementia drugs"},{"key":"S0007125000034929_ref3","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)92656-M"},{"key":"S0007125000034929_ref5","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"S0007125000034929_ref4","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1176\/ajp.147.2.239","article-title":"Treatment of Alzheimer\u2019 disease with short- and long-term oral THA and lecithin: a double blind study","volume":"147","author":"Fitten","year":"1990","journal-title":"American Journal of Psychiatry"},{"key":"S0007125000034929_ref12","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.34.7.939"},{"key":"S0007125000034929_ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199005033221804"}],"container-title":["British Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0007125000034929","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T19:36:44Z","timestamp":1558121804000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0007125000034929\/type\/journal_article"}},"subtitle":["Time Course of Changes in Cognitive Function and Practice Effects"],"short-title":[],"issued":{"date-parts":[[1992,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1992,1]]}},"alternative-id":["S0007125000034929"],"URL":"https:\/\/doi.org\/10.1192\/bjp.160.1.36","relation":{},"ISSN":["0007-1250","1472-1465"],"issn-type":[{"value":"0007-1250","type":"print"},{"value":"1472-1465","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,1]]}}}